SLC5A2 and hydrops fetalis: There were no differences in other cardioprotective medications, and no differences were observed between the two groups in the % patients on the three basic HF medications excluding SGLT2 inhibitors (the R Group: 42.0%, the N Group: 50.9%, p = 0.394) (Table 3).